AzTrials
AzTrials

Cardiovascular DiseasesPhase 3NCT00000546

Stress Reduction and Atherosclerotic CVD in Blacks

A Phase 3 study testing meditation in people with Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the effectiveness of stress reduction with Transcendental Meditation (TM) on left ventricular hypertrophy, left ventricular function, blood pressure, psychosocial stress and quality of life, and cardiovascular disease risk factors. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
meditation
How many people
Not given
Where
No sites listed yet
Study dates
Mar 1994to May 2005
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

No eligibility criteria

About this study

To evaluate the effectiveness of stress reduction with Transcendental Meditation (TM) on left ventricular hypertrophy, left ventricular function, blood pressure, psychosocial stress and quality of life, and cardiovascular disease risk factors.

Read the detailed description

BACKGROUND:

Blacks in the United States have disproportionately high rates of cardiovascular disease and mortality. Left ventricular hypertrophy, the primary manifestation of hypertensive heart disease and a major independent predictor of cardiovascular mortality, is twice as prevalent in Blacks with hypertension as in whites. Research has implicated chronic socio-environmental and psychological stress in the etiology of hypertension and left ventricular hypertrophy in Blacks. The trial seeks to investigate directly the impact of stress reduction programs for treating hypertensive heart disease in Blacks, since conventional antihypertensive drug therapies are less successful than expected. Moreover, these therapies frequently have adverse side effects on quality of life, and have low compliance rates, particularly in minorities.

DESIGN NARRATIVE:

The first study conducted between 1994 and 1999 used transcendental meditation for stress reduction in hypertensive heart disease. The study was randomized and blind. Subjects were randomized to practice TM for twelve months or to receive health education. The following measurements were obtained: left ventricular mass and function using echocardiography; clinic blood pressure and ambulatory blood pressure monitoring; urinary sodium excretion; alcohol consumption, weight, physical activity, cigarette smoking, and previous use of antihypertensive medication; various quality of life measures including physical functioning, psychosocial functioning, subjective symptoms, trait anger and anger-expression, stress impact scale, personal efficacy and health locus of control, social supports, ego development, and social desirability.

The trial was part of the Collaborative Projects on Minority Health, an Institute- initiated program to foster collaborative clinical research that focused on new and improved approaches for diagnosis, management, and prevention of cardiovascular, lung, and blood diseases in minorities. The trial was part of a two-grant collaboration on Nonpharmacologic Treatments for Managing Hypertension in African American Adults. Ernest Johnson (R01HL50516),the Program Coordinator collaborated with Robert Schneider (R01HL51519). The objectives of their studies were complementary and the collaborative arrangements allowed them to determine the effectiveness of different approaches to stress management in comparison with a control group that was comparable at both sites. In addition, the treatment schedules in both studies resulted in identical contact time, length of interventions, expectations regarding treatment effectiveness, and follow-up assessment periods. As a result, a considerable degree of pooling of data for analysis was possible.

Dr. Schneider's study was renewed in FY 1999 to conduct a randomized, single-blind, controlled, community-based trial involving 184 African American subjects with known coronary heart disease. Male and female subjects are enrolled at the on-going field site, Martin Luther King-Drew Medical Center in inner city Los Angeles. After baseline testing, subjects are randomized to either active stress reduction with TM or health education control-both in addition to usual medical care-and posttested after 12 months. The primary outcome is carotid artery atherosclerosis (IMT) measured non-invasively by quantitative B-mode ultrasonography. Secondary measures include traditional CVD risk factors (blood pressure, lipids, smoking, exercise), psychosocial stress, quality of life and cost effectiveness.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Being tested
meditation
Medical subject headings
Cardiovascular Diseases, Heart Diseases, Hypertension, Vascular Diseases, Coronary Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • meditationBehavioural

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Oct 1999 (estimated)
  2. Study startMar 1994
  3. Study completionMay 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
IDs, dates and publications
ClinicalTrials.gov ID
NCT00000546
Sponsor's protocol ID
90
Other IDs
R01HL051519
Status last verified
Oct 2005
First submitted
27 Oct 1999
Last updated
18 Feb 2016
Results posted
No

Publications

  • Schneider RH, Castillo-Richmond A, Alexander CN, Myers H, Kaushik V, Aranguri C, Norris K, Haney C, Rainforth M, Calderon R, Nidich S. Behavioral treatment of hypertensive heart disease in African Americans: rationale and design of a randomized controlled trial. Behav Med. 2001 Summer;27(2):83-95. doi: 10.1080/08964280109595775.

    PubMed 11763829
  • Castillo-Richmond A, Schneider RH, Alexander CN, Cook R, Myers H, Nidich S, Haney C, Rainforth M, Salerno J. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. Stroke. 2000 Mar;31(3):568-73. doi: 10.1161/01.str.31.3.568.

    PubMed 10700487
  • Calderon R Jr, Schneider RH, Alexander CN, Myers HF, Nidich SI, Haney C. Stress, stress reduction and hypercholesterolemia in African Americans: a review. Ethn Dis. 1999 Autumn;9(3):451-62.

    PubMed 10600068

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing meditation in people with Cardiovascular Diseases and Heart Diseases, run by National Heart, Lung, and Blood Institute (NHLBI).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00000546, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in